To the full analysis
Buyback calculator for Zealand Pharma
Zealand Pharma stock: key metrics
ZEAL.COZealand Pharma had an operating margin of 77.7% and a return on invested capital (ROIC) of 53% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2007 | 100.0% | −104.3% | −91.8% |
| 2008 | 100.0% | −79.4% | −60.0% |
| 2009 | 100.0% | −315.7% | −316.1% |
| 2010 | 100.0% | −124.4% | −119.8% |
| 2011 | 99.9% | 10.8% | 4.8% |
| 2012 | 92.9% | 14.5% | 16.3% |
| 2013 | 86.7% | −2,823.5% | −2,795.2% |
| 2014 | 91.0% | −47.8% | −42.3% |
| 2015 | 88.1% | −43.3% | −60.7% |
| 2016 | 86.6% | −49.3% | −65.6% |
| 2017 | 89.5% | −176.3% | −194.8% |
| 2018 | −374.6% | 1,717.9% | 1,530.6% |
| 2019 | 99.0% | −1,422.5% | −1,382.8% |
| 2020 | 74.4% | −234.6% | −239.7% |
| 2021 | 59.4% | −359.0% | −348.0% |
| 2022 | 70.5% | −785.3% | −928.6% |
| 2023 | 94.4% | −166.9% | −205.3% |
| 2024 | 87.4% | −2,029.3% | −1,720.9% |
| 2025 | 99.7% | 77.7% | 70.0% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2007 | −22.7% | −19.9% | −20.9% |
| 2008 | −16.2% | −15.4% | −15.0% |
| 2009 | −60.2% | −37.0% | −50.4% |
| 2010 | −25.7% | −31.8% | −23.2% |
| 2011 | 1.5% | 1.8% | 1.5% |
| 2012 | 7.4% | 6.9% | 7.0% |
| 2013 | −58.1% | −36.3% | −53.0% |
| 2014 | −25.7% | −13.8% | −10.9% |
| 2015 | −45.2% | −96.5% | −18.0% |
| 2016 | −55.3% | −42.2% | −22.2% |
| 2017 | −51.5% | −30.5% | −36.9% |
| 2018 | 52.1% | 68.2% | 47.3% |
| 2019 | −46.0% | −37.0% | −35.7% |
| 2020 | −71.9% | −47.8% | −44.0% |
| 2021 | −100.0% | −53.9% | −49.2% |
| 2022 | −100.0% | −41.9% | −62.7% |
| 2023 | −44.2% | −29.7% | −35.5% |
| 2024 | −12.5% | −18.6% | −11.3% |
| 2025 | 43.5% | 53.0% | 39.2% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = DKK 6.7461)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 1 May 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.